Most people that are diagnosed with a metastatic cancer, that is a cancer that is aggressive and moves beyond its primary point of origin, have about a 97 or 98 per cent chance of eventually dying from that cancer. Something has to be done about this and that’s what hundreds of companies like ourselves are doing.
Indronoxil is the first drug that specifically knocks out this master switch in tumour cells. It means we can now kill highly resistant cancer cells that have resisted all existing therapies previously. It works with all of the commonly used cancer drugs. In the test tube and in animals it increases the sensitivity to chemotherapy by over 2000 times. We have also found no evidence of toxicity.
So our objective is to bring to market a drug that will become hopefully standard treatment with common chemotherapy and radiotherapy, that works in most, if not all cancers and will give you long term results and allow drugs to be lowered to safer levels.
